September 24, 2026
When people hear about semaglutide or tirzepatide, they often think about weight loss, blood sugar, or appetite control. But there is another part of the body that deserves attention: the kidneys.
This raises an important question. Can GLP 1 medications cause kidney disease, or could they actually help protect the kidneys?
The answer is more complicated than a simple yes or no.
Current research suggests that semaglutide and tirzepatide may have beneficial effects on kidney health, particularly in people with type 2 diabetes, overweight or obesity, and certain cardiovascular or kidney risks. At the same time, these medications can cause side effects such as nausea, vomiting, and diarrhea. If these symptoms lead to significant dehydration, kidney function can temporarily worsen and, in some cases, acute kidney injury can occur.
That is why using these medications under proper medical supervision matters.
GLP 1 stands for glucagon like peptide 1, a hormone involved in blood sugar regulation, appetite, and digestion.
Semaglutide is a GLP 1 receptor agonist. Tirzepatide works on both the GLP 1 and GIP receptors.
Although these medications are not simply "kidney medicines," they can affect several factors that are closely connected to kidney health.
High blood sugar, high blood pressure, excess body weight, insulin resistance, and cardiovascular disease can all increase the risk of chronic kidney disease. Improving some of these conditions may also reduce stress on the kidneys.
This is one reason researchers have become increasingly interested in the possible kidney benefits of GLP 1 based medications.
One of the most important studies in this area is the FLOW trial.
The study included more than 3,500 people with type 2 diabetes and chronic kidney disease. Participants received either semaglutide or placebo and were followed for a median of 3.4 years.
Researchers found that people receiving semaglutide had a lower risk of major kidney disease events compared with those receiving placebo. Semaglutide was also associated with a slower decline in estimated kidney function.
In the trial, the risk of the primary kidney related outcome was 24 percent lower in the semaglutide group. The study included people who already had chronic kidney disease, meaning the findings are particularly important for understanding how semaglutide may affect people who are already at increased kidney risk.
The findings were significant enough that the U.S. prescribing information for Ozempic was updated to include reducing the risk of sustained kidney function decline, end stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
This does not mean that everyone taking semaglutide will automatically be protected from kidney disease. The results came from a specific population and under controlled clinical conditions.
Still, the findings provide encouraging evidence that semaglutide can have effects beyond weight and blood sugar control.
Tirzepatide is a little different because it activates two hormone pathways: GLP 1 and GIP.
Researchers are also studying whether tirzepatide can benefit kidney health.
In analyses of clinical trials involving people with type 2 diabetes, tirzepatide was associated with reductions in the urine albumin to creatinine ratio, commonly called UACR.
Why does that matter?
Albumin is a protein that normally stays in the blood. When the kidneys become damaged, more albumin can leak into the urine. Higher levels of urinary albumin can be a sign of kidney damage and are associated with a higher risk of kidney disease progression.
A pooled analysis of the SURPASS 1 through 5 trials found that tirzepatide reduced UACR compared with the control treatments. The researchers noted that part of the reduction appeared to be related to weight loss.
More recent analyses have also found reductions in albuminuria among people with overweight or obesity, including people with and without type 2 diabetes, without evidence of harmful changes in estimated kidney function. However, researchers continue to study whether these changes translate into long term protection against kidney failure.
So, while the kidney findings for tirzepatide are promising, it is important not to describe the medication as a proven treatment for every form of kidney disease.
This is where the story becomes important.
Semaglutide and tirzepatide are not generally considered medications that directly damage the kidneys in the way certain kidney toxic drugs can.
However, they can cause gastrointestinal side effects.
Nausea, vomiting, and diarrhea can result in substantial fluid loss. If a person becomes severely dehydrated, the amount of blood flowing through the kidneys can fall. This can lead to acute kidney injury.
The FDA prescribing information for semaglutide includes a warning about acute kidney injury associated with volume depletion. Reported cases have occurred in the setting of gastrointestinal reactions that caused dehydration.
Tirzepatide carries a similar warning. Its prescribing information states that diarrhea, nausea, and vomiting can cause dehydration, which may lead to kidney problems.
This is one reason why persistent vomiting or diarrhea should not simply be ignored while taking a GLP 1 based medication.
Not necessarily.
There is an important difference between a medication potentially contributing to acute kidney injury through dehydration and a medication causing chronic kidney disease.
Current evidence actually points in the other direction for some patients.
Semaglutide has demonstrated kidney related benefits in people with type 2 diabetes and chronic kidney disease. Tirzepatide has been associated with reductions in albuminuria and improvements in several metabolic factors connected to kidney risk.
At the same time, these medications can create situations that may temporarily put the kidneys under stress, particularly when gastrointestinal side effects lead to significant fluid loss.
Both facts can be true.
The relationship between weight and kidney health is easy to overlook.
Excess body weight can contribute to high blood pressure, insulin resistance, type 2 diabetes, inflammation, and other metabolic problems. These conditions can increase the workload on the kidneys and contribute to chronic kidney disease.
When a person loses excess weight and improves blood sugar and blood pressure, some of the factors that place stress on the kidneys may also improve.
This is one possible reason GLP 1 based medications have attracted attention in kidney research.
However, weight loss alone does not guarantee better kidney health. Someone can lose weight and still have high blood pressure, diabetes, kidney disease, or another condition that requires medical treatment.
If you are taking semaglutide or tirzepatide, kidney health should be part of the conversation with your healthcare provider, especially if you already have diabetes, high blood pressure, chronic kidney disease, or a history of kidney problems.
Your healthcare provider may consider tests such as:
• Serum creatinine
• Estimated glomerular filtration rate, or eGFR
• Urine albumin to creatinine ratio
• Blood glucose or A1C
• Blood pressure
• Electrolytes when appropriate
You should also tell your healthcare provider if you develop persistent vomiting or diarrhea, cannot keep fluids down, are urinating much less than usual, feel unusually weak or dizzy, or have other symptoms that could suggest significant dehydration or kidney problems.
Do not change your dose or stop a prescribed medication based only on information from a blog.
Two people can take the same medication and have very different medical histories.
One person may have normal kidney function. Another may already have chronic kidney disease. Someone else may have diabetes, take blood pressure medication, or be taking other medicines that affect fluid balance.
That is why the question should not simply be, "Does semaglutide or tirzepatide help the kidneys?"
A better question is:
"Is this medication appropriate for my health, my kidney function, my other medications, and my treatment goals?"
That answer should come from a qualified healthcare provider who knows your medical history and can monitor your progress.
The current evidence gives us a more balanced picture.
Semaglutide has demonstrated kidney related benefits in people with type 2 diabetes and chronic kidney disease, including a reduced risk of major kidney outcomes in the FLOW trial.
Tirzepatide has shown promising effects on markers of kidney health, particularly reductions in urinary albumin, although researchers are still studying its long term ability to prevent kidney disease progression.
At the same time, both medications can cause gastrointestinal side effects that may lead to dehydration and potentially acute kidney injury.
So GLP 1 based medications should not be viewed as either "kidney damaging" or "kidney protecting" for everyone.
They are medications that can affect several metabolic processes connected to kidney health. Whether the overall effect is beneficial for a particular person depends on that person's health, medical history, kidney function, medications, dose, and response to treatment.
If you are considering semaglutide or tirzepatide, talk with your healthcare provider first. Proper dosing, hydration, monitoring, and follow up can make a major difference in using these medications safely.
Your kidneys may not get much attention when you start thinking about weight loss, but they are part of the bigger picture. And as research continues, it is becoming increasingly clear that metabolic health and kidney health are closely connected.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch Traberg, H., Lausvig, N. L., & Pratley, R. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 391(2), 109–121.
U.S. Food and Drug Administration. (2026). Ozempic (semaglutide) prescribing information. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2026). Mounjaro (tirzepatide) prescribing information. U.S. Department of Health and Human Services.
Heerspink, H. J. L., et al. (2025). Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: Pooled post hoc analysis from the randomized active and placebo controlled SURPASS 1 to 5 clinical trials. Diabetes Care.
Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025). Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: The SUMMIT trial. Journal of the American College of Cardiology, 85(18), 1721–1735.
